Conference Reports for NATAP

(IDRW) International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; June 4-8, 2013; Toronto, ON, Canada Back

Primary and Secondary Analyses of Emergent Drug Resistance through Week 48 from the STaR Study: Rilpivirine/Emtricitabine/Tenofovir DF vs. Efavirenz/Emtricitabine/Tenofovir DF Single-Tablet Regimens       Reported by Jules Levin International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies June 4-8, 2013 Toronto, Canada   DP Porter, R Kulkarni, T Fralich, MD Miller, and KL White Gilead Sciences Inc, Foster City, CA, United States   Glasgow/2012: STaR Study: Single-Tablet Regimen Emtricitabine/Rilpivirine/Tenofovir DF is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults Week 48 Results - (11/16/12)   Glasgow/2012 Gilead press release: Gilead 's Complera® Non-Inferior to Atripla® Among Treatment-Naïve HIV Patients - (11/16/12)